{"url_path":"/sec/wint/8-k/2026-07-22/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/946486/0001437749-26-024009-index.html","accession_number":"0001437749-26-024009","cik":"0000946486","ticker":"WINT","issuer_name":"WINDTREE THERAPEUTICS INC /DE/","edgar_url":"https://www.sec.gov/Archives/edgar/data/946486/0001437749-26-024009-index.html","primary_entity_key":"0000946486","primary_entity_name":"WINDTREE THERAPEUTICS INC /DE/"},"word_count":126,"has_tables":true,"body_markdown":"**Item 1.01. Entry into a Material Definitive Agreement**\n\n \n\nAs disclosed in a press release dated December 23, 2025, on December 16th, 2025 Windtree Therapeutics, Inc. (“Windtree” or “the Company”) signed an agreement for the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. (“SPO”), a Delaware limited liability company.\n\n \n\nPursuant to the agreement, Windtree is entitled to 20% of any future proceeds received by SPO. This would include global commercial net revenue in acute heart failure (AHF) if approved by regulatory authorities. If SPO conducts a financing of at least $10MM to fund development of the assets, Windtree would receive a payment of $700k from the proceeds. Additionally, as part of the agreement, Windtree will transfer certain cardiovascular drug candidate development payables to SPO."}